Fate therapeutics announces termination of collaboration agreement with janssen, pipeline prioritization, next-generation programs, and key 2023 initiatives

Ended 2022 with approximately $475 million in cash, cash equivalents & receivables; 3-year operational runway provided through pipeline prioritization and expense reduction

FATE Ratings Summary

FATE Quant Ranking